Pulvomycin, an inhibitor of prokaryotic protein biosynthesis

Area of Science:

• Microbiology
• Molecular Biology
• Biochemistry

Background:

• Antibiotic resistance is a growing global health concern.
• Novel antibiotics are needed to combat resistant bacterial strains.
• Streptoverticillium mobaraense is a source of bioactive compounds.

Purpose of the Study:

• To identify and characterize antibiotic 1063-Z.
• To elucidate the mechanism of action of pulvomycin on bacterial protein biosynthesis.
• To investigate the potential of pulvomycin as a therapeutic agent.

Main Methods:

• Isolation and identification of antibiotic 1063-Z from Streptoverticillium mobaraense.
• Assaying protein biosynthesis inhibition in Bacillus brevis.
• Studying poly(U)-directed poly(Phe) synthesis in cell-free systems of Bacillus brevis and Escherichia coli.
• Investigating the effect of pulvomycin on phenylalanine (Phe) transfer to tRNA.

Main Results:

• Antibiotic 1063-Z was identified as pulvomycin.
• Pulvomycin significantly inhibited protein biosynthesis in growing Bacillus brevis cells.
• Cell-free systems of Bacillus brevis and Escherichia coli showed high susceptibility to pulvomycin's inhibitory effects on poly(Phe) synthesis.
• Pulvomycin did not interfere with the transfer of phenylalanine to tRNA.

Conclusions:

• Pulvomycin's primary target is the polypeptide chain elongation step in protein biosynthesis.
• The findings suggest pulvomycin acts on the ribosome during protein synthesis.
• Pulvomycin represents a potential new antibiotic targeting bacterial protein synthesis.